| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Beijing Kawin Technology Share-Holding Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.70 |
| 52 Week High | CN¥37.63 |
| 52 Week Low | CN¥18.50 |
| Beta | 0.99 |
| 1 Month Change | -8.61% |
| 3 Month Change | 4.65% |
| 1 Year Change | -2.46% |
| 3 Year Change | -17.19% |
| 5 Year Change | n/a |
| Change since IPO | -34.05% |
Recent News & Updates
Shareholder Returns
| 688687 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 14.9% | 0.3% | 1.6% |
| 1Y | -2.5% | -24.2% | -15.1% |
Return vs Industry: 688687 exceeded the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 688687 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 688687 volatility | |
|---|---|
| 688687 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 688687's share price has been volatile over the past 3 months.
Volatility Over Time: 688687's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 584 | Desheng Zhou | www.kawin.com.cn |
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company’s products include recombinant human interferon alfa-2b injection; vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; and compound glycyrrhizin.
Beijing Kawin Technology Share-Holding Co., Ltd. Fundamentals Summary
| 688687 fundamental statistics | |
|---|---|
| Market cap | CN¥4.72b |
| Earnings (TTM) | CN¥117.53m |
| Revenue (TTM) | CN¥1.43b |
39.5x
P/E Ratio3.2x
P/S RatioIs 688687 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688687 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.43b |
| Cost of Revenue | CN¥243.33m |
| Gross Profit | CN¥1.19b |
| Other Expenses | CN¥1.07b |
| Earnings | CN¥117.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 83.01% |
| Net Profit Margin | 8.21% |
| Debt/Equity Ratio | 5.9% |
How did 688687 perform over the long term?
See historical performance and comparison